数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Murray S. Kessler Director, President, Chief Executive Officer 61 1096.72万美元 未持股 2021-04-01
Adriana Karaboutis Independent Director 58 39.10万美元 未持股 2021-04-01
Theodore R. Samuels Independent Director 66 39.55万美元 未持股 2021-04-01
Erica L. Mann Independent Director 62 38.75万美元 未持股 2021-04-01
Orlando D. Ashford Independent Director 52 0.41万美元 未持股 2021-04-01
Katherine Doyle Independent Director 53 33.64万美元 未持股 2021-04-01
Rolf A. Classon Independent Director 75 53.30万美元 未持股 2021-04-01
Bradley A. Alford Independent Director 64 38.75万美元 未持股 2021-04-01
Geoffrey M. Parker Independent Director 56 38.75万美元 未持股 2021-04-01
Jeffrey B. Kindler Independent Director 65 40.00万美元 未持股 2021-04-01

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Murray S. Kessler Director, President, Chief Executive Officer 61 1096.72万美元 未持股 2021-04-01
James E. Dillard III Executive Vice President and Chief Scientific Officer 57 271.68万美元 未持股 2021-04-01
Robert Willis Executive Vice President and Chief Human Resources Officer 52 未披露 未持股 2021-04-01
Ronald Janish Chief Transformation Officer, Executive Vice President of Global Operations and Supply Chain 55 未披露 未持股 2021-04-01
Svend Andersen Executive Vice President and President, Consumer Self-Care International 59 252.19万美元 未持股 2021-04-01
Richard S. Sorota Executive Vice President and General Manager of Consumer Self-Care Americas 57 250.04万美元 未持股 2021-04-01
Todd W. Kingma Executive Vice President, General Counsel and Secretary 61 249.82万美元 未持股 2021-04-01
Grainne Quinn Executive Vice President, Chief Medical Officer 51 未披露 未持股 2021-04-01
Thomas M. Farrington Executive Vice President and Chief Information Officer 63 未披露 未持股 2021-04-01
Sharon Kochan Executive Vice President and President, RX Pharmaceuticals 52 148.13万美元 未持股 2021-04-01
Raymond P. Silcock Executive Vice President and Chief Financial Officer 70 335.94万美元 未持股 2021-04-01

董事简历

中英对照 |  中文 |  英文
Murray S. Kessler

Murray S. Kessler于2010年9月加入罗瑞拉德烟草公司并担任其公司主管、总裁兼首席执行官职务,并于2011年1月1日被提名为董事会主席。在加入罗瑞拉德烟草公司之前,他在奥驰亚集团担任副主席。以及自2009年1月至2009年6月期间内在UST有限责任公司担任总裁兼首席执行官,UST有限责任公司是奥驰亚集团的全资子公司。在2009年之前,他在UST有限责任公司担任董事会主席,并负责美国无烟烟草公司的主要业务。他于2008年1月在米歇尔酒庄任职,并于2007年在UST有限责任公司担任总裁兼首席执行官。自2005年11月至2006年12月期间内他开始担任总裁兼运营总监,并于2000年4月在至2005年10月期间内在美国无烟烟草公司担任总裁。自2005年至2008年期间内他在UST有限责任公司担任公司主管。在加入UST有限责任公司之前,他对消费性包装品有着18年的工作经验,其中他曾在坎贝尔汤和高乐氏公司任职。


Murray S. Kessler was appointed President, Chief Executive Officer and Board Member of Perrigo Company plc, effective October 8 2018. Before joining Perrigo, Mr. Kessler served as the Chairman of the board of directors, President and CEO of Lorillard, Inc. 2010-2015. He served as Vice Chair of Altria, Inc. -2009 and President and CEO of UST, Inc. (2000-2009), a wholly owned subsidiary. Previous to his time at UST, Mr. Kessler had over 18 years of consumer-packaged goods experience with companies including Vlasic Foods International, Campbell Soup and The Clorox Company. In addition to his board service at Lorillard, Mr. Kessler previously served on the board of directors of Reynolds-American, Inc. from 2015 to 2017. Mr. Kessler has served as voluntary President of the United States Equestrian Federation from 2015 to January 2020.
Murray S. Kessler于2010年9月加入罗瑞拉德烟草公司并担任其公司主管、总裁兼首席执行官职务,并于2011年1月1日被提名为董事会主席。在加入罗瑞拉德烟草公司之前,他在奥驰亚集团担任副主席。以及自2009年1月至2009年6月期间内在UST有限责任公司担任总裁兼首席执行官,UST有限责任公司是奥驰亚集团的全资子公司。在2009年之前,他在UST有限责任公司担任董事会主席,并负责美国无烟烟草公司的主要业务。他于2008年1月在米歇尔酒庄任职,并于2007年在UST有限责任公司担任总裁兼首席执行官。自2005年11月至2006年12月期间内他开始担任总裁兼运营总监,并于2000年4月在至2005年10月期间内在美国无烟烟草公司担任总裁。自2005年至2008年期间内他在UST有限责任公司担任公司主管。在加入UST有限责任公司之前,他对消费性包装品有着18年的工作经验,其中他曾在坎贝尔汤和高乐氏公司任职。
Murray S. Kessler was appointed President, Chief Executive Officer and Board Member of Perrigo Company plc, effective October 8 2018. Before joining Perrigo, Mr. Kessler served as the Chairman of the board of directors, President and CEO of Lorillard, Inc. 2010-2015. He served as Vice Chair of Altria, Inc. -2009 and President and CEO of UST, Inc. (2000-2009), a wholly owned subsidiary. Previous to his time at UST, Mr. Kessler had over 18 years of consumer-packaged goods experience with companies including Vlasic Foods International, Campbell Soup and The Clorox Company. In addition to his board service at Lorillard, Mr. Kessler previously served on the board of directors of Reynolds-American, Inc. from 2015 to 2017. Mr. Kessler has served as voluntary President of the United States Equestrian Federation from 2015 to January 2020.
Adriana Karaboutis

Adriana Karaboutis于2020年7月22日当选为董事会成员。自2017年8月以来,她一直担任国家电网的集团首席信息和数字官,负责整个集团数字战略、信息系统和服务、数字安全和风险以及整体安全的开发。在她的职业生涯中,Karaboutis领导了几个全球品牌的数字化转型,包括Biogen Inc .,Dell Inc .,通用汽车公司和福特汽车公司。从2014年9月到2017年3月,她担任Biogen Inc.的技术、业务解决方案和企业事务执行副总裁,在Biogen Inc.她介绍了领先的数字合作伙伴,以建立通过核心信息技术战略在药物发现、开发和交付过程中提供价值的能力。在加入Biogen之前,Karaboutis在Dell担任副总裁和全球首席信息官,在推动创新文化和持续业务流程改进方面发挥了重要作用。20多年来,Karaboutis一直致力于技术创新,以推动复杂制造和加工行业的业务转型。Karaboutis持有韦恩州立大学(Wayne State University)计算机科学学士学位。自2017年5月以来,Karaboutis女士一直担任Perrigo Company plc (NYSE,非处方医疗保健产品提供商)的董事会成员。2015年2月至2020年5月,她还担任Advance Auto Parts, Inc.(纽约证券交易所)的董事会成员,这是一家汽车售后市场零部件供应商;2016年2月至2017年12月,她担任Blue Cross Blue Shield of Massachusetts的董事会成员。


Adriana Karaboutis,served as Chief Information and Digital Officer of National Grid PLC, one of the world's largest public utility companies focused on transmitting and distributing electricity and gas in the UK and northeast US. She previously served as Executive Vice President, Technology, Business Solutions and Corporate Affairs at Biogen Inc., a global biotechnology company, from September 2014 to March 2017. In that role, she introduced leading digital and data science capabilities that unlocked value across the drug discovery, development, and delivery processes. From December 2015, she also oversaw global public affairs, government affairs, public policy and patient advocacy. From March 2010 to September 2014, Ms. Karaboutis was Vice President and Global Chief Information Officer of Dell, Inc., a global technology company. Ms. Karaboutis previously spent more than 20 years at General Motors Company and Ford Motor Company in various international leadership positions, including global production planning, computer-integrated manufacturing, supply chain operations and information technology. Ms. Karaboutis serves as a director of Perrigo Company plc, a global over-the-counter consumer goods and pharmaceutical company, and Savills plc, a British real estate services company. She previously served on the boards of directors of Aspen Technology, Advance Auto Parts and Blue Cross Blue Shield of Massachusetts.
Adriana Karaboutis于2020年7月22日当选为董事会成员。自2017年8月以来,她一直担任国家电网的集团首席信息和数字官,负责整个集团数字战略、信息系统和服务、数字安全和风险以及整体安全的开发。在她的职业生涯中,Karaboutis领导了几个全球品牌的数字化转型,包括Biogen Inc .,Dell Inc .,通用汽车公司和福特汽车公司。从2014年9月到2017年3月,她担任Biogen Inc.的技术、业务解决方案和企业事务执行副总裁,在Biogen Inc.她介绍了领先的数字合作伙伴,以建立通过核心信息技术战略在药物发现、开发和交付过程中提供价值的能力。在加入Biogen之前,Karaboutis在Dell担任副总裁和全球首席信息官,在推动创新文化和持续业务流程改进方面发挥了重要作用。20多年来,Karaboutis一直致力于技术创新,以推动复杂制造和加工行业的业务转型。Karaboutis持有韦恩州立大学(Wayne State University)计算机科学学士学位。自2017年5月以来,Karaboutis女士一直担任Perrigo Company plc (NYSE,非处方医疗保健产品提供商)的董事会成员。2015年2月至2020年5月,她还担任Advance Auto Parts, Inc.(纽约证券交易所)的董事会成员,这是一家汽车售后市场零部件供应商;2016年2月至2017年12月,她担任Blue Cross Blue Shield of Massachusetts的董事会成员。
Adriana Karaboutis,served as Chief Information and Digital Officer of National Grid PLC, one of the world's largest public utility companies focused on transmitting and distributing electricity and gas in the UK and northeast US. She previously served as Executive Vice President, Technology, Business Solutions and Corporate Affairs at Biogen Inc., a global biotechnology company, from September 2014 to March 2017. In that role, she introduced leading digital and data science capabilities that unlocked value across the drug discovery, development, and delivery processes. From December 2015, she also oversaw global public affairs, government affairs, public policy and patient advocacy. From March 2010 to September 2014, Ms. Karaboutis was Vice President and Global Chief Information Officer of Dell, Inc., a global technology company. Ms. Karaboutis previously spent more than 20 years at General Motors Company and Ford Motor Company in various international leadership positions, including global production planning, computer-integrated manufacturing, supply chain operations and information technology. Ms. Karaboutis serves as a director of Perrigo Company plc, a global over-the-counter consumer goods and pharmaceutical company, and Savills plc, a British real estate services company. She previously served on the boards of directors of Aspen Technology, Advance Auto Parts and Blue Cross Blue Shield of Massachusetts.
Theodore R. Samuels

Theodore R. Samuels,曾任职Capital Group Companies(1981年至2016年)。他曾担任 the Capital Guardian Trust Company的总裁(2010年至2016年),也曾担任资本集团代表,专注于长期投资(从2014年到2015年)。他曾担任投资组合经理(从1990年到2016年),期间任职Capital Group的多种管理和投资委员会。他也曾担任Capital Group Foundation的董事会成员,以及Capital Group Foundation Investment Committee和the Capital International North America Proxy Committee的主席。他曾任职于the Capital Group Finance Committee(2013年至2016年),此前曾任职于the Capital Group Board和the Capital Group Audit Committee。他也担任Tuft''s President''s Council、the Harvard West Cost Council的联席主席,也是the Harvard College Fund Executive Committee的成员。他是Children''s Hospital Los Angeles的受托人,在那里他曾担任联席主席(2012年至2015年),也是the Pasadena City College Foundation的受托人。


Theodore R. Samuels,has more than 35 years of experience in the financial industry, currently serving as the Lead Independent Director of Bristol-Myers Squibb and as an independent director of Centene Corporation. From 2017 until May 2023, Mr. Samuels served on the board of directors of Perrigo Company plc, and from January 2017 until October 2021, he served on the board of directors for Stamps.com. Prior to these roles, Mr. Samuels served as the President of Capital Guardian Trust Company, a subsidiary of Capital Group, one of the largest investment management firms in the world, from 2010 to 2016. Mr. Samuels was an investor at Capital Group and served on numerous management and investment committees from 1981 to 2017.Mr. Samuels holds a Bachelor of Arts and Masters of Business Administration from Harvard University.
Theodore R. Samuels,曾任职Capital Group Companies(1981年至2016年)。他曾担任 the Capital Guardian Trust Company的总裁(2010年至2016年),也曾担任资本集团代表,专注于长期投资(从2014年到2015年)。他曾担任投资组合经理(从1990年到2016年),期间任职Capital Group的多种管理和投资委员会。他也曾担任Capital Group Foundation的董事会成员,以及Capital Group Foundation Investment Committee和the Capital International North America Proxy Committee的主席。他曾任职于the Capital Group Finance Committee(2013年至2016年),此前曾任职于the Capital Group Board和the Capital Group Audit Committee。他也担任Tuft''s President''s Council、the Harvard West Cost Council的联席主席,也是the Harvard College Fund Executive Committee的成员。他是Children''s Hospital Los Angeles的受托人,在那里他曾担任联席主席(2012年至2015年),也是the Pasadena City College Foundation的受托人。
Theodore R. Samuels,has more than 35 years of experience in the financial industry, currently serving as the Lead Independent Director of Bristol-Myers Squibb and as an independent director of Centene Corporation. From 2017 until May 2023, Mr. Samuels served on the board of directors of Perrigo Company plc, and from January 2017 until October 2021, he served on the board of directors for Stamps.com. Prior to these roles, Mr. Samuels served as the President of Capital Guardian Trust Company, a subsidiary of Capital Group, one of the largest investment management firms in the world, from 2010 to 2016. Mr. Samuels was an investor at Capital Group and served on numerous management and investment committees from 1981 to 2017.Mr. Samuels holds a Bachelor of Arts and Masters of Business Administration from Harvard University.
Erica L. Mann

Erica L. Mann 2019年2月起担任凯洛格董事。曼恩女士曾于2016年1月至2018年3月担任拜耳股份公司管理委员会成员,并于2016年1月至2018年3月担任拜耳股份公司CH董事会成员。从2011年3月至2015年12月,担任拜耳医疗保健公司消费者健康总裁。在加入拜耳医疗保健之前,曼恩女士是辉瑞营养健康集团的总裁兼总经理,辉瑞营养保健是全球业务部门,业务遍及全球80多个国家,并是该公司的成员。在2008年至2011年期间担任辉瑞高级管理团队的职务。曼恩女士在收购辉瑞公司后加入辉瑞公司,后者担任营养部门高级副总裁,帮助建立了新的营养业务部门的形态和战略方向。她在财富500强公司中也有丰富的经验,包括礼来公司(Ely Lilly&Company)和强生公司(Johnson&Johnson),并在南非,澳大利亚,新西兰,德国,瑞士和美国担任领导职务。曼恩女士是Perrigo Company plc和DSM(一家全球营养,健康与可持续生活公司)的董事。她曾于2018年8月至2019年11月担任SOHO Flordis International董事。


Erica L. Mann,Former President Consumer Health of Bayer Healthcare LLC. Ms. Mann previously served as a member of the Board of Management of Bayer AG, a pharmaceutical and biotechnology company, from January 2016 to March 2018, and Bayer AG CH from January 2016 to March 2018. She was also President Consumer Health, Bayer Healthcare LLC from March 2011 to December 2015. Before joining Bayer HealthCare, Ms. Mann was President and General Manager of Pfizer Nutritional Health, a global business unit with operations in more than 80 countries, and served as a member of the Pfizer Senior Management Team from 2008 to 2011. Ms. Mann joined Pfizer upon its acquisition of Wyeth, where as Senior Vice President of Nutrition, she helped establish the shape and strategic direction of the new nutrition business unit. She also has significant experience at other Fortune 500 companies, including Ely Lilly & Company and Johnson & Johnson, and has held leadership positions in South Africa, Australia, New Zealand, Germany, Switzerland and the United States. Ms. Mann is a director of Perrigo Company plc, DSM, a global Nutrition, Health and Sustainable Living company, and Blackmores LTD, a leading Australian Natural Health company.
Erica L. Mann 2019年2月起担任凯洛格董事。曼恩女士曾于2016年1月至2018年3月担任拜耳股份公司管理委员会成员,并于2016年1月至2018年3月担任拜耳股份公司CH董事会成员。从2011年3月至2015年12月,担任拜耳医疗保健公司消费者健康总裁。在加入拜耳医疗保健之前,曼恩女士是辉瑞营养健康集团的总裁兼总经理,辉瑞营养保健是全球业务部门,业务遍及全球80多个国家,并是该公司的成员。在2008年至2011年期间担任辉瑞高级管理团队的职务。曼恩女士在收购辉瑞公司后加入辉瑞公司,后者担任营养部门高级副总裁,帮助建立了新的营养业务部门的形态和战略方向。她在财富500强公司中也有丰富的经验,包括礼来公司(Ely Lilly&Company)和强生公司(Johnson&Johnson),并在南非,澳大利亚,新西兰,德国,瑞士和美国担任领导职务。曼恩女士是Perrigo Company plc和DSM(一家全球营养,健康与可持续生活公司)的董事。她曾于2018年8月至2019年11月担任SOHO Flordis International董事。
Erica L. Mann,Former President Consumer Health of Bayer Healthcare LLC. Ms. Mann previously served as a member of the Board of Management of Bayer AG, a pharmaceutical and biotechnology company, from January 2016 to March 2018, and Bayer AG CH from January 2016 to March 2018. She was also President Consumer Health, Bayer Healthcare LLC from March 2011 to December 2015. Before joining Bayer HealthCare, Ms. Mann was President and General Manager of Pfizer Nutritional Health, a global business unit with operations in more than 80 countries, and served as a member of the Pfizer Senior Management Team from 2008 to 2011. Ms. Mann joined Pfizer upon its acquisition of Wyeth, where as Senior Vice President of Nutrition, she helped establish the shape and strategic direction of the new nutrition business unit. She also has significant experience at other Fortune 500 companies, including Ely Lilly & Company and Johnson & Johnson, and has held leadership positions in South Africa, Australia, New Zealand, Germany, Switzerland and the United States. Ms. Mann is a director of Perrigo Company plc, DSM, a global Nutrition, Health and Sustainable Living company, and Blackmores LTD, a leading Australian Natural Health company.
Orlando D. Ashford

Orlando D. Ashford自2020年12月起担任Perrigo Company Plc董事。Ashford先生是纽约Sycamore Partners的战略顾问,分别自2011年12月和2020年10月起担任ITT,Inc.和ArrayTechnologies,Inc.的董事会成员。他最近曾担任Holland America Line的总裁,领导屡获殊荣的Cruise Line的品牌和业务,此前曾担任全球咨询公司Mercer的人才业务部门总裁。任职Mercer公司之前,他曾担任Mercer公司的母公司Marsh & McLennan Companies的高级副总裁、首席人力资源和通信官,也曾担任Coca-Cola Company、Motorola公司的多种领导职务。Ashford先生拥有普渡大学的组织领导和工业技术理学学士学位和理学硕士学位。他也是执行董事领导委员会和ROADS Charter 高中的董事会成员。他还担任Purdue大学技术学院 和NFL球员协会咨询委员会委员。


Orlando D. Ashford has been a director since December 2020. Mr. Ashford is a strategic advisor with Sycamore Partners in New York, and serves on the board of directors of ITT, Inc., and Array Technologies, Inc., since December 2011 and October 2020 respectively. He most recently served as president of Holland America Line, leading the award-winning cruise line's brand and business, and was previously president of the Talent Business Segment for Mercer, the global consulting firm. Previous to Mercer he served as senior vice president, chief human resources and communications officer of Mercer's parent company, Marsh & McLennan Companies and also has held several other leadership roles during the course of his career at Coca-Cola Company and Motorola Inc. Mr. Ashford holds a Bachelor of Science degree and Master of Science degree in Organizational Leadership and Industrial Technology from Purdue University.
Orlando D. Ashford自2020年12月起担任Perrigo Company Plc董事。Ashford先生是纽约Sycamore Partners的战略顾问,分别自2011年12月和2020年10月起担任ITT,Inc.和ArrayTechnologies,Inc.的董事会成员。他最近曾担任Holland America Line的总裁,领导屡获殊荣的Cruise Line的品牌和业务,此前曾担任全球咨询公司Mercer的人才业务部门总裁。任职Mercer公司之前,他曾担任Mercer公司的母公司Marsh & McLennan Companies的高级副总裁、首席人力资源和通信官,也曾担任Coca-Cola Company、Motorola公司的多种领导职务。Ashford先生拥有普渡大学的组织领导和工业技术理学学士学位和理学硕士学位。他也是执行董事领导委员会和ROADS Charter 高中的董事会成员。他还担任Purdue大学技术学院 和NFL球员协会咨询委员会委员。
Orlando D. Ashford has been a director since December 2020. Mr. Ashford is a strategic advisor with Sycamore Partners in New York, and serves on the board of directors of ITT, Inc., and Array Technologies, Inc., since December 2011 and October 2020 respectively. He most recently served as president of Holland America Line, leading the award-winning cruise line's brand and business, and was previously president of the Talent Business Segment for Mercer, the global consulting firm. Previous to Mercer he served as senior vice president, chief human resources and communications officer of Mercer's parent company, Marsh & McLennan Companies and also has held several other leadership roles during the course of his career at Coca-Cola Company and Motorola Inc. Mr. Ashford holds a Bachelor of Science degree and Master of Science degree in Organizational Leadership and Industrial Technology from Purdue University.
Katherine Doyle

Katherine Doyle自2020年7月以来一直担任Perrigo的董事。从2016年到2019年,Doyle女士担任电子商务品牌Swanson Health Products,Inc.的首席执行官。在此之前,她于2014年至2016年担任直接面向消费者的健康业务的独立顾问。Doyle女士曾于2011年至2014年在雅培公司担任各种执行领导职务,包括雅培营养产品部总裁,在此之前,担任儿科营养副总裁兼总经理。在2011年之前,Doyle女士在麦肯锡公司(McKinsey & Company,Inc.)获得了超过20年的经验,包括担任10年的负责人,在欧洲,亚洲,拉丁美洲和非洲的消费者包装商品,消费者医疗保健和零售部门工作。自2019年4月以来,Doyle女士一直担任全球全渠道杂货零售商Ahold Delhaize的董事,她在Ahold Delhaize担任可持续发展与创新委员会主席并担任审核委员会成员。此前,她曾于2017年8月至2019年6月在BemisCompany,Inc.(一家前公开上市的全球包装公司)董事会任职,在那里她曾担任其审计,提名和治理委员会成员。


Katherine Doyle has been a director of Perrigo since July 2020. From 2016 to 2019 Ms. Doyle served as the Chief Executive Officer of Swanson Health Products, Inc, an e-commerce brand. Prior to that, she served as an independent consultant to direct-to-consumer wellness businesses from 2014 to 2016. Ms. Doyle previously worked at Abbott Laboratories in various executive leadership roles from 2011 to 2014 including President of the Abbott Nutrition Product Division and, before that, Vice President and General Manager of Pediatric Nutrition. Prior to 2011 Ms. Doyle gained more than 20 years of experience at McKinsey & Company, Inc., including 10 years as Principal, working in the consumer-packaged goods, consumer healthcare and retail sectors across Europe, Asia, Latin America and Africa. Since April 2019 Ms. Doyle has served as a director of Ahold Delhaize, a global omnichannel grocery retailer, where she is the Chair of the Sustainability and Innovation Committee and serves on the Audit Committee. Previously, she served on the board of Bemis Company, Inc., a former publicly traded global packaging company, from August 2017 to June 2019 where she served on its Audit and Nomination and Governance Committees.
Katherine Doyle自2020年7月以来一直担任Perrigo的董事。从2016年到2019年,Doyle女士担任电子商务品牌Swanson Health Products,Inc.的首席执行官。在此之前,她于2014年至2016年担任直接面向消费者的健康业务的独立顾问。Doyle女士曾于2011年至2014年在雅培公司担任各种执行领导职务,包括雅培营养产品部总裁,在此之前,担任儿科营养副总裁兼总经理。在2011年之前,Doyle女士在麦肯锡公司(McKinsey & Company,Inc.)获得了超过20年的经验,包括担任10年的负责人,在欧洲,亚洲,拉丁美洲和非洲的消费者包装商品,消费者医疗保健和零售部门工作。自2019年4月以来,Doyle女士一直担任全球全渠道杂货零售商Ahold Delhaize的董事,她在Ahold Delhaize担任可持续发展与创新委员会主席并担任审核委员会成员。此前,她曾于2017年8月至2019年6月在BemisCompany,Inc.(一家前公开上市的全球包装公司)董事会任职,在那里她曾担任其审计,提名和治理委员会成员。
Katherine Doyle has been a director of Perrigo since July 2020. From 2016 to 2019 Ms. Doyle served as the Chief Executive Officer of Swanson Health Products, Inc, an e-commerce brand. Prior to that, she served as an independent consultant to direct-to-consumer wellness businesses from 2014 to 2016. Ms. Doyle previously worked at Abbott Laboratories in various executive leadership roles from 2011 to 2014 including President of the Abbott Nutrition Product Division and, before that, Vice President and General Manager of Pediatric Nutrition. Prior to 2011 Ms. Doyle gained more than 20 years of experience at McKinsey & Company, Inc., including 10 years as Principal, working in the consumer-packaged goods, consumer healthcare and retail sectors across Europe, Asia, Latin America and Africa. Since April 2019 Ms. Doyle has served as a director of Ahold Delhaize, a global omnichannel grocery retailer, where she is the Chair of the Sustainability and Innovation Committee and serves on the Audit Committee. Previously, she served on the board of Bemis Company, Inc., a former publicly traded global packaging company, from August 2017 to June 2019 where she served on its Audit and Nomination and Governance Committees.
Rolf A. Classon

Rolf A. Classon2004年5月加入我们董事会,2005年4月被任命为公司董事会主席,之前从2005年3月至2005年4月他曾经担任副主席, Classon先生目前担任Hill-Rom公司(Hill-Rom Corporation)的董事会董事,从2005年5月至2006年3同时还担任临时首席执行官,Classon克拉森先生目前还担任Tecan集团有限公司(Tecan Group Ltd)董事会董事以及费森尤斯医药((Fresenius Medical Care))董事会成员,从1997年1月至2011年5月他还担任过ENZON制药公司(Enzon Pharmaceuticals, Inc)的董事会成员,从2011年5月至2011年10月作为EKR Therapeutics公司(EKR Therapeutics, Inc)的董事会主席,从2002年10月到2004年7月, Classon先生是拜耳医药保健(Bayer HealthCare AG)的执行委员会主席,这是拜耳集团(Bayer AG)的子公司。从1995年到2002年,他曾担任拜耳诊断(Bayer Diagnostics)的总裁,1991年至1995年他担任拜耳诊断(Bayer Diagnostics)的执行副总裁。在此之前,他在法玛西亚公司(Pharmacia Corporation)担任过多个管理职位。Classon先生于1965年获得工程哥德堡学校(the Gothenburg School of Engineering)化学工程证书,于1969年获得哥德堡大学(the Gothenburg University)商业学士学位。


Rolf A. Classon has been a director of Perrigo since May 2017. Mr. Classon served as Interim President and Chief Executive Officer of Hillenbrand Industries, a global diversified industrial company, from May 2005 until March 2006. From 2002 until June 2004 Mr. Classon served as Chairman of the Executive Committee of Bayer Healthcare AG, a subsidiary of Bayer AG. Mr. Classon served as President of Bayer Diagnostics from 1995 to 2002 and as Executive Vice President from 1991 to 1995. Prior to 1991 Mr. Classon held various management positions with Pharmacia Corporation. Mr. Classon serves as a director of Fresenius Medical Care AG and Co. since May 2012 and Catalent, Inc. since July 2014. Mr. Classon also served as a director of Hill-Rom Holdings, Inc., from July 2001 to March 2018 Aerocrine AB, Stockholm from May 2013 to July 2015 Auxilium Pharmaceuticals from July 2005 to January 2015 and Tecan Group, Ltd. from 2009 to April 2018.
Rolf A. Classon2004年5月加入我们董事会,2005年4月被任命为公司董事会主席,之前从2005年3月至2005年4月他曾经担任副主席, Classon先生目前担任Hill-Rom公司(Hill-Rom Corporation)的董事会董事,从2005年5月至2006年3同时还担任临时首席执行官,Classon克拉森先生目前还担任Tecan集团有限公司(Tecan Group Ltd)董事会董事以及费森尤斯医药((Fresenius Medical Care))董事会成员,从1997年1月至2011年5月他还担任过ENZON制药公司(Enzon Pharmaceuticals, Inc)的董事会成员,从2011年5月至2011年10月作为EKR Therapeutics公司(EKR Therapeutics, Inc)的董事会主席,从2002年10月到2004年7月, Classon先生是拜耳医药保健(Bayer HealthCare AG)的执行委员会主席,这是拜耳集团(Bayer AG)的子公司。从1995年到2002年,他曾担任拜耳诊断(Bayer Diagnostics)的总裁,1991年至1995年他担任拜耳诊断(Bayer Diagnostics)的执行副总裁。在此之前,他在法玛西亚公司(Pharmacia Corporation)担任过多个管理职位。Classon先生于1965年获得工程哥德堡学校(the Gothenburg School of Engineering)化学工程证书,于1969年获得哥德堡大学(the Gothenburg University)商业学士学位。
Rolf A. Classon has been a director of Perrigo since May 2017. Mr. Classon served as Interim President and Chief Executive Officer of Hillenbrand Industries, a global diversified industrial company, from May 2005 until March 2006. From 2002 until June 2004 Mr. Classon served as Chairman of the Executive Committee of Bayer Healthcare AG, a subsidiary of Bayer AG. Mr. Classon served as President of Bayer Diagnostics from 1995 to 2002 and as Executive Vice President from 1991 to 1995. Prior to 1991 Mr. Classon held various management positions with Pharmacia Corporation. Mr. Classon serves as a director of Fresenius Medical Care AG and Co. since May 2012 and Catalent, Inc. since July 2014. Mr. Classon also served as a director of Hill-Rom Holdings, Inc., from July 2001 to March 2018 Aerocrine AB, Stockholm from May 2013 to July 2015 Auxilium Pharmaceuticals from July 2005 to January 2015 and Tecan Group, Ltd. from 2009 to April 2018.
Bradley A. Alford

Bradley A. Alford,2006年1月到2012年10月他担任雀巢美国(一家营养、保健和健康公司)的董事长和首席执行官;2003年到2005年12月担任雀巢的品牌公司雀巢美国的总裁兼首席执行官。


Bradley A. Alford,Nestle USA, a nutrition, health and wellness company,Chairman & CEO from January 2006 to October 2012.Nestle Brands Company, an operating unit of Nestle USA,President & CEO from 2003 to December 2005.Current: Perrigo Company PLC,Past Five Years:Conagra Brands, Inc.
Bradley A. Alford,2006年1月到2012年10月他担任雀巢美国(一家营养、保健和健康公司)的董事长和首席执行官;2003年到2005年12月担任雀巢的品牌公司雀巢美国的总裁兼首席执行官。
Bradley A. Alford,Nestle USA, a nutrition, health and wellness company,Chairman & CEO from January 2006 to October 2012.Nestle Brands Company, an operating unit of Nestle USA,President & CEO from 2003 to December 2005.Current: Perrigo Company PLC,Past Five Years:Conagra Brands, Inc.
Geoffrey M. Parker

Geoffrey M. Parker自2016年11月起担任Perrigo的董事。自2017年4月以来,Parker先生一直担任生物制药公司Tricida, Inc.的首席财务官。Parker先生曾于2010年9月至2015年5月担任生物制药公司Anacor制药的首席财务官。从1997年到2009年,Parker先生在高盛领导西海岸医疗保健投资银行业务,在那里他为生物技术、生命科学工具和医疗器械行业的领先公司提供咨询。Parker先生自2009年12月起担任ChemoCentryx董事会成员。Parker先生曾于2016年6月至2019年11月担任基因组健康董事会成员,并于2016年3月至2017年12月担任Sunesis Pharmaceuticals董事会成员。


Geoffrey M. Parker has been a director of Perrigo since November 2016. Since April 2017 Mr. Parker has served as Chief Financial Officer of Tricida, Inc., a biopharmaceutical company. Mr. Parker previously served as Chief Financial Officer of Anacor Pharmaceuticals, a biopharmaceutical company, from September 2010 to May 2015. From 1997 to 2009 Mr. Parker led the West Coast Healthcare Investment Banking practice at Goldman Sachs, where he advised leading companies in the biotechnology, life science tools and medical device industries. Mr. Parker has served as a member of the board of directors of ChemoCentryx since December 2009. Mr. Parker previously served on the board of directors of Genomic Health from June 2016 until November 2019 and of Sunesis Pharmaceuticals from March 2016 until December 2017.
Geoffrey M. Parker自2016年11月起担任Perrigo的董事。自2017年4月以来,Parker先生一直担任生物制药公司Tricida, Inc.的首席财务官。Parker先生曾于2010年9月至2015年5月担任生物制药公司Anacor制药的首席财务官。从1997年到2009年,Parker先生在高盛领导西海岸医疗保健投资银行业务,在那里他为生物技术、生命科学工具和医疗器械行业的领先公司提供咨询。Parker先生自2009年12月起担任ChemoCentryx董事会成员。Parker先生曾于2016年6月至2019年11月担任基因组健康董事会成员,并于2016年3月至2017年12月担任Sunesis Pharmaceuticals董事会成员。
Geoffrey M. Parker has been a director of Perrigo since November 2016. Since April 2017 Mr. Parker has served as Chief Financial Officer of Tricida, Inc., a biopharmaceutical company. Mr. Parker previously served as Chief Financial Officer of Anacor Pharmaceuticals, a biopharmaceutical company, from September 2010 to May 2015. From 1997 to 2009 Mr. Parker led the West Coast Healthcare Investment Banking practice at Goldman Sachs, where he advised leading companies in the biotechnology, life science tools and medical device industries. Mr. Parker has served as a member of the board of directors of ChemoCentryx since December 2009. Mr. Parker previously served on the board of directors of Genomic Health from June 2016 until November 2019 and of Sunesis Pharmaceuticals from March 2016 until December 2017.
Jeffrey B. Kindler

Jeffrey B. Kindler,一些私人保健服务公司董事、顾问及投资者。他现任一家私营制药公司Centrexion公司的首席执行官。除了Chipotle,他还在两家其他上市公司的董事会及几个非营利组织工作过;两家上市公司是Intrexon公司(纽约证券交易所:XON)和Siga科技公司(纳克达斯全球交易市场:SIGA)。他于2010年12月从辉瑞制药公司退休,曾于此担任董事长兼首席执行官。他于2002年进入辉瑞担任高级副总裁兼总顾问,且被指派的职务职责不断提高,直到2006年被任命为首席执行官。在进入辉瑞之前,他是麦当劳公司的行政人员;且在2001年期间,他接手负责该公司的合伙品牌集团(Chipotle也包含在内)。


Jeffrey B. Kindler has been a director of Perrigo since February 2017. Mr. Kindler has served as CEO of Centrexion Corporation, a privately held bio therapeutics company that develops pain therapies, since 2013. Prior to this, Mr. Kindler was a Venture Partner at Lux Capital from 2012 until January 2020 Executive Chairman of vTv from July 2015 to November 2019 Chairman and CEO of Pfizer, Vice President of Litigation and Legal Policy at General Electric Company, Executive Vice President and General Counsel at McDonald’s, and President at Partner Brands. In addition, Mr. Kindler has been a director of Terns Pharmaceutical since December 2020 in February 2021 Terns became public company; a director Intrexon, now known as Precigen, since 2011; and PPD since May 2017 in February 2020 PDD became a public company. Mr. Kindler also serves as an advisor of a number of healthcare companies. Mr. Kindler served on the board of Siga Technologies from 2013 until May 2020 and vTv Therapeutics from 2025 until December 2020.
Jeffrey B. Kindler,一些私人保健服务公司董事、顾问及投资者。他现任一家私营制药公司Centrexion公司的首席执行官。除了Chipotle,他还在两家其他上市公司的董事会及几个非营利组织工作过;两家上市公司是Intrexon公司(纽约证券交易所:XON)和Siga科技公司(纳克达斯全球交易市场:SIGA)。他于2010年12月从辉瑞制药公司退休,曾于此担任董事长兼首席执行官。他于2002年进入辉瑞担任高级副总裁兼总顾问,且被指派的职务职责不断提高,直到2006年被任命为首席执行官。在进入辉瑞之前,他是麦当劳公司的行政人员;且在2001年期间,他接手负责该公司的合伙品牌集团(Chipotle也包含在内)。
Jeffrey B. Kindler has been a director of Perrigo since February 2017. Mr. Kindler has served as CEO of Centrexion Corporation, a privately held bio therapeutics company that develops pain therapies, since 2013. Prior to this, Mr. Kindler was a Venture Partner at Lux Capital from 2012 until January 2020 Executive Chairman of vTv from July 2015 to November 2019 Chairman and CEO of Pfizer, Vice President of Litigation and Legal Policy at General Electric Company, Executive Vice President and General Counsel at McDonald’s, and President at Partner Brands. In addition, Mr. Kindler has been a director of Terns Pharmaceutical since December 2020 in February 2021 Terns became public company; a director Intrexon, now known as Precigen, since 2011; and PPD since May 2017 in February 2020 PDD became a public company. Mr. Kindler also serves as an advisor of a number of healthcare companies. Mr. Kindler served on the board of Siga Technologies from 2013 until May 2020 and vTv Therapeutics from 2025 until December 2020.

高管简历

中英对照 |  中文 |  英文
Murray S. Kessler

Murray S. Kessler于2010年9月加入罗瑞拉德烟草公司并担任其公司主管、总裁兼首席执行官职务,并于2011年1月1日被提名为董事会主席。在加入罗瑞拉德烟草公司之前,他在奥驰亚集团担任副主席。以及自2009年1月至2009年6月期间内在UST有限责任公司担任总裁兼首席执行官,UST有限责任公司是奥驰亚集团的全资子公司。在2009年之前,他在UST有限责任公司担任董事会主席,并负责美国无烟烟草公司的主要业务。他于2008年1月在米歇尔酒庄任职,并于2007年在UST有限责任公司担任总裁兼首席执行官。自2005年11月至2006年12月期间内他开始担任总裁兼运营总监,并于2000年4月在至2005年10月期间内在美国无烟烟草公司担任总裁。自2005年至2008年期间内他在UST有限责任公司担任公司主管。在加入UST有限责任公司之前,他对消费性包装品有着18年的工作经验,其中他曾在坎贝尔汤和高乐氏公司任职。


Murray S. Kessler was appointed President, Chief Executive Officer and Board Member of Perrigo Company plc, effective October 8 2018. Before joining Perrigo, Mr. Kessler served as the Chairman of the board of directors, President and CEO of Lorillard, Inc. 2010-2015. He served as Vice Chair of Altria, Inc. -2009 and President and CEO of UST, Inc. (2000-2009), a wholly owned subsidiary. Previous to his time at UST, Mr. Kessler had over 18 years of consumer-packaged goods experience with companies including Vlasic Foods International, Campbell Soup and The Clorox Company. In addition to his board service at Lorillard, Mr. Kessler previously served on the board of directors of Reynolds-American, Inc. from 2015 to 2017. Mr. Kessler has served as voluntary President of the United States Equestrian Federation from 2015 to January 2020.
Murray S. Kessler于2010年9月加入罗瑞拉德烟草公司并担任其公司主管、总裁兼首席执行官职务,并于2011年1月1日被提名为董事会主席。在加入罗瑞拉德烟草公司之前,他在奥驰亚集团担任副主席。以及自2009年1月至2009年6月期间内在UST有限责任公司担任总裁兼首席执行官,UST有限责任公司是奥驰亚集团的全资子公司。在2009年之前,他在UST有限责任公司担任董事会主席,并负责美国无烟烟草公司的主要业务。他于2008年1月在米歇尔酒庄任职,并于2007年在UST有限责任公司担任总裁兼首席执行官。自2005年11月至2006年12月期间内他开始担任总裁兼运营总监,并于2000年4月在至2005年10月期间内在美国无烟烟草公司担任总裁。自2005年至2008年期间内他在UST有限责任公司担任公司主管。在加入UST有限责任公司之前,他对消费性包装品有着18年的工作经验,其中他曾在坎贝尔汤和高乐氏公司任职。
Murray S. Kessler was appointed President, Chief Executive Officer and Board Member of Perrigo Company plc, effective October 8 2018. Before joining Perrigo, Mr. Kessler served as the Chairman of the board of directors, President and CEO of Lorillard, Inc. 2010-2015. He served as Vice Chair of Altria, Inc. -2009 and President and CEO of UST, Inc. (2000-2009), a wholly owned subsidiary. Previous to his time at UST, Mr. Kessler had over 18 years of consumer-packaged goods experience with companies including Vlasic Foods International, Campbell Soup and The Clorox Company. In addition to his board service at Lorillard, Mr. Kessler previously served on the board of directors of Reynolds-American, Inc. from 2015 to 2017. Mr. Kessler has served as voluntary President of the United States Equestrian Federation from 2015 to January 2020.
James E. Dillard III

James E. Dillard III,曾担任Altria Client Services的监管事务高级副总裁兼首席创新官。 他主要负责管理Altria的监管和创新活动。2015年,他供职于运营企业,以增强其用于解决成人烟草用户偏好的五年产品投资组合计划,同时他还通过频繁进行新产品概念试验来简化和加快产品开发进程,并且发展创新目标和指标来跟踪组织进程。他也成功领导了公司在药监局(FDA)的重要审批活动。


James E. Dillard III was named Executive Vice President and Chief Scientific Officer in January 2019. Mr. Dillard joined Perrigo from Altria Group, Inc., where he served as Senior Vice President, Research, Development and Sciences and Chief Innovation Officer from January 2009 to May 2018. During his tenure with Altria Group, Mr. Dillard led the creation of the Regulatory Affairs function in 2009 and also served as Chief Innovation Officer for Altria Client Services and Senior Vice President of Research, Development & Regulatory Affairs for Altria Group. He held science and technology leadership roles with U.S. Smokeless Tobacco Company, an Altria Group Inc. operating company, from 2001 to 2009. Mr. Dillard worked for the U.S. Food and Drug Administration between 1987 and 2001 as Director of the Division of Cardiovascular and Respiratory Devices, as well as in various leadership roles in the Center for Devices and Radiological Health and the Office of Device Evaluation.
James E. Dillard III,曾担任Altria Client Services的监管事务高级副总裁兼首席创新官。 他主要负责管理Altria的监管和创新活动。2015年,他供职于运营企业,以增强其用于解决成人烟草用户偏好的五年产品投资组合计划,同时他还通过频繁进行新产品概念试验来简化和加快产品开发进程,并且发展创新目标和指标来跟踪组织进程。他也成功领导了公司在药监局(FDA)的重要审批活动。
James E. Dillard III was named Executive Vice President and Chief Scientific Officer in January 2019. Mr. Dillard joined Perrigo from Altria Group, Inc., where he served as Senior Vice President, Research, Development and Sciences and Chief Innovation Officer from January 2009 to May 2018. During his tenure with Altria Group, Mr. Dillard led the creation of the Regulatory Affairs function in 2009 and also served as Chief Innovation Officer for Altria Client Services and Senior Vice President of Research, Development & Regulatory Affairs for Altria Group. He held science and technology leadership roles with U.S. Smokeless Tobacco Company, an Altria Group Inc. operating company, from 2001 to 2009. Mr. Dillard worked for the U.S. Food and Drug Administration between 1987 and 2001 as Director of the Division of Cardiovascular and Respiratory Devices, as well as in various leadership roles in the Center for Devices and Radiological Health and the Office of Device Evaluation.
Robert Willis

Robert Willis担任人力资源全球业务副总裁近六年后,于2019年3月被任命为执行副总裁兼首席人力资源官。加入Perrigo之前,Willis先生在中东的Fawaz Alhokair集团,英国和爱尔兰的GE Capital,北美和国际上的DoubleClick以及欧洲的Norkom Technologies担任过人力资源领导者,积累了20多年的经验。他还是黑白集团的合伙人和创始成员。


Robert Willis, has served on our board of directors and as Vice Chairman - Capital Markets, since July 2021 and previously served as the Company's President from April 2016 until the completion of its initial business combination with Computex in April 2021. Dr. Willis has served as a Managing Partner of the SPAC Operations Group at Navigation since April 2020. Dr. Willis became the President of nsoro, a turnkey wireless installation services provider, in 2007 and served in that capacity until its acquisition by MasTec in 2008 and, following its acquisition, served in an advisory role from 2010 through July 2016. From December 2013 until December 2015 Dr. Willis served as Chairman of U.S. Shale Solutions, Inc., a shale services company which he founded in 2013. Prior to nsoro, Dr. Willis served as Chief Executive Officer of Foxcode Inc., a merchant-banking firm. In July 2004 Dr. Willis founded Gaming VC, S.A., an online gaming enterprise which completed a GBP 81 million initial public offering in London in 2004 and served as a member of its board and as its Finance Director until 2007. Prior to that, Dr. Willis was the founder and Chief Executive Officer of Alpine Computer Systems, Inc., a systems integration engineering company established in the 1980s that grew rapidly and was acquired by Delphi Group plc. in 1996 at which time he became Senior Vice President and Chief Information Officer of the parent company. Dr. Willis was awarded a Doctorate in Humane Letters Hon. from Newbury College in Boston, MA, in May 2001.
Robert Willis担任人力资源全球业务副总裁近六年后,于2019年3月被任命为执行副总裁兼首席人力资源官。加入Perrigo之前,Willis先生在中东的Fawaz Alhokair集团,英国和爱尔兰的GE Capital,北美和国际上的DoubleClick以及欧洲的Norkom Technologies担任过人力资源领导者,积累了20多年的经验。他还是黑白集团的合伙人和创始成员。
Robert Willis, has served on our board of directors and as Vice Chairman - Capital Markets, since July 2021 and previously served as the Company's President from April 2016 until the completion of its initial business combination with Computex in April 2021. Dr. Willis has served as a Managing Partner of the SPAC Operations Group at Navigation since April 2020. Dr. Willis became the President of nsoro, a turnkey wireless installation services provider, in 2007 and served in that capacity until its acquisition by MasTec in 2008 and, following its acquisition, served in an advisory role from 2010 through July 2016. From December 2013 until December 2015 Dr. Willis served as Chairman of U.S. Shale Solutions, Inc., a shale services company which he founded in 2013. Prior to nsoro, Dr. Willis served as Chief Executive Officer of Foxcode Inc., a merchant-banking firm. In July 2004 Dr. Willis founded Gaming VC, S.A., an online gaming enterprise which completed a GBP 81 million initial public offering in London in 2004 and served as a member of its board and as its Finance Director until 2007. Prior to that, Dr. Willis was the founder and Chief Executive Officer of Alpine Computer Systems, Inc., a systems integration engineering company established in the 1980s that grew rapidly and was acquired by Delphi Group plc. in 1996 at which time he became Senior Vice President and Chief Information Officer of the parent company. Dr. Willis was awarded a Doctorate in Humane Letters Hon. from Newbury College in Boston, MA, in May 2001.
Ronald Janish

Ronald Janish,他曾于2015年10月被任命为执行副总裁,负责全球营运与供应链管理 。他曾担任高级副总裁,负责国际和Rx操作(从2012年到2015年),以及Perrigo公司的澳大利亚的董事总经理(从2010年到2012年)。此前,他曾担任Perrigo公司的高级副总裁,负责国际市场拓展、中国的商业发展和全球采购。


Ronald Janish was named Chief Transformation Officer in January 2019 and Executive Vice President of Global Operations and Supply Chain in October 2015. He served as Senior Vice President of International and Rx Operations from 2012 until 2015 and as Managing Director of Perrigo’s Australian operations from 2010 to 2012. Previously, he held Senior Vice President roles for Perrigo in International Market Development, China Business Development and Global Procurement.
Ronald Janish,他曾于2015年10月被任命为执行副总裁,负责全球营运与供应链管理 。他曾担任高级副总裁,负责国际和Rx操作(从2012年到2015年),以及Perrigo公司的澳大利亚的董事总经理(从2010年到2012年)。此前,他曾担任Perrigo公司的高级副总裁,负责国际市场拓展、中国的商业发展和全球采购。
Ronald Janish was named Chief Transformation Officer in January 2019 and Executive Vice President of Global Operations and Supply Chain in October 2015. He served as Senior Vice President of International and Rx Operations from 2012 until 2015 and as Managing Director of Perrigo’s Australian operations from 2010 to 2012. Previously, he held Senior Vice President roles for Perrigo in International Market Development, China Business Development and Global Procurement.
Svend Andersen

Svend Andersen,他于2017年2月被任命为执行副总裁、总裁,负责消费者保健国际。加入Perrigo公司之前,他曾担任LEO-Pharma的欧洲执行副总裁。此前,他曾领导Hospira, Inc.的欧洲、中东和非洲业务,也曾负责Actavis的西欧部门的制药、非专利药、OTC和医院产品业务,还曾领导Alpharma公司的欧洲、中东和非洲业务(公司被Actavis收购之前)。


Svend Andersen was named Executive Vice President and President, Consumer Self-Care International in February 2017. Prior to joining Perrigo in May 2016 Mr. Andersen served as Executive Vice President - Europe for LEO-Pharma from December 2015 to May 2016. Prior to that, he was Regional President and Corporate officer at Hospira, Inc.’s Europe, Middle East and Africa “EMEA” business for five years, was Executive Vice President responsible for the Western European division’s pharmaceuticals, generics, OTC and hospital products businesses at Actavis from 2008 to 2015 including leading Alpharma’s EMEA businesses prior to its acquisition by Actavis, and prior to that, spent 10 years with Ferrosan (A Novo Nordisk Subsidiary) specialized in OTC and consumer health products as Vice President for Global Commercial Operations.
Svend Andersen,他于2017年2月被任命为执行副总裁、总裁,负责消费者保健国际。加入Perrigo公司之前,他曾担任LEO-Pharma的欧洲执行副总裁。此前,他曾领导Hospira, Inc.的欧洲、中东和非洲业务,也曾负责Actavis的西欧部门的制药、非专利药、OTC和医院产品业务,还曾领导Alpharma公司的欧洲、中东和非洲业务(公司被Actavis收购之前)。
Svend Andersen was named Executive Vice President and President, Consumer Self-Care International in February 2017. Prior to joining Perrigo in May 2016 Mr. Andersen served as Executive Vice President - Europe for LEO-Pharma from December 2015 to May 2016. Prior to that, he was Regional President and Corporate officer at Hospira, Inc.’s Europe, Middle East and Africa “EMEA” business for five years, was Executive Vice President responsible for the Western European division’s pharmaceuticals, generics, OTC and hospital products businesses at Actavis from 2008 to 2015 including leading Alpharma’s EMEA businesses prior to its acquisition by Actavis, and prior to that, spent 10 years with Ferrosan (A Novo Nordisk Subsidiary) specialized in OTC and consumer health products as Vice President for Global Commercial Operations.
Richard S. Sorota

Richard S. Sorota于2020年3月被任命为Perrigo Company Plc执行副总裁兼美洲消费者自我保健总经理。他曾于2015年7月至2020年3月担任Ranir Global Holdings LLC的首席执行官兼总裁。Sorota先生在一般管理,销售,市场营销和产品开发方面有着悠久的经验。任职Bissell Inc.期间,他曾担任全球销售与市场营销的高级副总裁兼总经理,随后担任全球商业运营执行副总裁。曾在Harman International担任消费者业务总裁,在The ScottsMiracle-GroCompany担任高级副总裁和总经理,在Philips Electronics担任营销和创新的高级领导职务,在Procter&Gamble担任品牌管理。Sorota在通用电气公司开始了他的金融生涯。


Richard S. Sorota was named Executive Vice President and General Manager of Consumer Self-Care Americas in March 2020. He previously served as Chief Executive Officer and President of Ranir Global Holdings LLC from July 2015 to March 2020. Mr. Sorota has a long history of experience in general management, sales, marketing and product development. While at BISSELL Inc., he served as Senior Vice President and General Manager for Global Sales and Marketing and then Executive Vice President of Global Commercial Operations. Previous roles include serving as President of Consumer Business for HARMAN International, Senior Vice President and General Manager at The Scotts Miracle-Gro Company, and senior leadership roles in marketing and innovation for Philips Electronics and brand management at Procter & Gamble. Rich began his career in Finance at General Electric.
Richard S. Sorota于2020年3月被任命为Perrigo Company Plc执行副总裁兼美洲消费者自我保健总经理。他曾于2015年7月至2020年3月担任Ranir Global Holdings LLC的首席执行官兼总裁。Sorota先生在一般管理,销售,市场营销和产品开发方面有着悠久的经验。任职Bissell Inc.期间,他曾担任全球销售与市场营销的高级副总裁兼总经理,随后担任全球商业运营执行副总裁。曾在Harman International担任消费者业务总裁,在The ScottsMiracle-GroCompany担任高级副总裁和总经理,在Philips Electronics担任营销和创新的高级领导职务,在Procter&Gamble担任品牌管理。Sorota在通用电气公司开始了他的金融生涯。
Richard S. Sorota was named Executive Vice President and General Manager of Consumer Self-Care Americas in March 2020. He previously served as Chief Executive Officer and President of Ranir Global Holdings LLC from July 2015 to March 2020. Mr. Sorota has a long history of experience in general management, sales, marketing and product development. While at BISSELL Inc., he served as Senior Vice President and General Manager for Global Sales and Marketing and then Executive Vice President of Global Commercial Operations. Previous roles include serving as President of Consumer Business for HARMAN International, Senior Vice President and General Manager at The Scotts Miracle-Gro Company, and senior leadership roles in marketing and innovation for Philips Electronics and brand management at Procter & Gamble. Rich began his career in Finance at General Electric.
Todd W. Kingma

Todd W. Kingma,2006年5月,被任命为Perrigo Company执行副总裁。2003年至2006年5月,他担任副总裁、法律总顾问、秘书。此前,1991-2003,他在Pharmacia Corporation担任过各种职务;最后的职务是全球特种业务的副总裁、副法律总顾问。


Todd W. Kingma was named Executive Vice President in May 2006. He served as Vice President, General Counsel and Secretary from 2003 to May 2006. Previously, Mr. Kingma held various positions at Pharmacia Corporation from 1991 through 2003. His last position with Pharmacia Corporation was Vice President and Associate General Counsel, Global Specialty Operations.
Todd W. Kingma,2006年5月,被任命为Perrigo Company执行副总裁。2003年至2006年5月,他担任副总裁、法律总顾问、秘书。此前,1991-2003,他在Pharmacia Corporation担任过各种职务;最后的职务是全球特种业务的副总裁、副法律总顾问。
Todd W. Kingma was named Executive Vice President in May 2006. He served as Vice President, General Counsel and Secretary from 2003 to May 2006. Previously, Mr. Kingma held various positions at Pharmacia Corporation from 1991 through 2003. His last position with Pharmacia Corporation was Vice President and Associate General Counsel, Global Specialty Operations.
Grainne Quinn

Grainne Quinn,2011年10月,被任命为首席医学官。他于2009年1月加入Elan;2010年4月,被任命为全球药物警戒与风险管理部副总裁,目前她继续管理该部门。加入Elan之前,她在Quintiles Ireland Ltd担任过一些领导职务,其中包括医学与科学服务执行总监、医师安全全球总监。另外,她曾是马萨诸塞州波士顿、明尼苏达州Minneapolis的一名内科执业医生。他在爱尔兰的Royal College of Surgeons获得医学学位;1995年,在American Board of Internal Medicine获得内科专家认证。


Grainne Quinn was named Executive Vice President in July 2016 and has served as Chief Medical Officer since November 2015. Prior to that she served as Vice President and Head of Global Patient Safety from January 2014 until November 2015. Dr. Quinn was Vice President and Head of Global Pharmacovigilance and Risk Management for Elan from April 2009 until December 2013 when the Company acquired Elan.
Grainne Quinn,2011年10月,被任命为首席医学官。他于2009年1月加入Elan;2010年4月,被任命为全球药物警戒与风险管理部副总裁,目前她继续管理该部门。加入Elan之前,她在Quintiles Ireland Ltd担任过一些领导职务,其中包括医学与科学服务执行总监、医师安全全球总监。另外,她曾是马萨诸塞州波士顿、明尼苏达州Minneapolis的一名内科执业医生。他在爱尔兰的Royal College of Surgeons获得医学学位;1995年,在American Board of Internal Medicine获得内科专家认证。
Grainne Quinn was named Executive Vice President in July 2016 and has served as Chief Medical Officer since November 2015. Prior to that she served as Vice President and Head of Global Patient Safety from January 2014 until November 2015. Dr. Quinn was Vice President and Head of Global Pharmacovigilance and Risk Management for Elan from April 2009 until December 2013 when the Company acquired Elan.
Thomas M. Farrington

Thomas M. Farrington于2006年10月被任命为高级副总裁和首席信息官。他之前从2003年到2006年10月担任F. Dohmen Co。首席信息官,除此之外还曾担任JASCORP LLC分部总裁。在此之前,Farrington从1999年到2003年在Farrington信息技术和金融领域担任多个高级职位。


Thomas M. Farrington was named Executive Vice President and Chief Information Officer in November 2015. He formerly served as Senior Vice President and Chief Information Officer from October 2006 to November 2015.
Thomas M. Farrington于2006年10月被任命为高级副总裁和首席信息官。他之前从2003年到2006年10月担任F. Dohmen Co。首席信息官,除此之外还曾担任JASCORP LLC分部总裁。在此之前,Farrington从1999年到2003年在Farrington信息技术和金融领域担任多个高级职位。
Thomas M. Farrington was named Executive Vice President and Chief Information Officer in November 2015. He formerly served as Senior Vice President and Chief Information Officer from October 2006 to November 2015.
Sharon Kochan

Sharon Kochan,Kochan于2012年8月被任命为International执行副总裁和总经理。他从2007年3月到2012年7月担任Rx Pharmaceuticals执行副总裁和总经理;2005年到2007年3月担任业务开发和战略高级副总裁。Kochan从2001年到2005年(公司收购Agis)之前担任Agis Industries -1983 Ltd.业务开发副总裁。


Sharon Kochan was named Executive Vice President and President, RX Pharmaceuticals in October 2018. He served as Executive Vice President and President, Branded Consumer Healthcare International from February 2017 to October 2018. He served as Executive Vice President and General Manager, Consumer Healthcare International from August 2012 to February 2017. He served as Executive Vice President, General Manager of Prescription Pharmaceuticals from March 2007 to July 2012 and as Senior Vice President of Business Development and Strategy from March 2005 to March 2007. Mr. Kochan was Vice President, Business Development of Agis Industries -1983 Ltd. from July 2001 until the acquisition of Agis by the Company in March 2005.
Sharon Kochan,Kochan于2012年8月被任命为International执行副总裁和总经理。他从2007年3月到2012年7月担任Rx Pharmaceuticals执行副总裁和总经理;2005年到2007年3月担任业务开发和战略高级副总裁。Kochan从2001年到2005年(公司收购Agis)之前担任Agis Industries -1983 Ltd.业务开发副总裁。
Sharon Kochan was named Executive Vice President and President, RX Pharmaceuticals in October 2018. He served as Executive Vice President and President, Branded Consumer Healthcare International from February 2017 to October 2018. He served as Executive Vice President and General Manager, Consumer Healthcare International from August 2012 to February 2017. He served as Executive Vice President, General Manager of Prescription Pharmaceuticals from March 2007 to July 2012 and as Senior Vice President of Business Development and Strategy from March 2005 to March 2007. Mr. Kochan was Vice President, Business Development of Agis Industries -1983 Ltd. from July 2001 until the acquisition of Agis by the Company in March 2005.
Raymond P. Silcock

Raymond P. Silcock,他曾担任执行副总裁和首席财务官(2013年6月以来)。加入Diamond之前,他是Great Atlantic & Pacific Tea Company A&P的高级副总裁和首席财务官(2012年3月到2013年2月),也曾担任财政主管(从2011年12月到2011年3月)。他是A&P and Palm Ventures公司的独立管理顾问(从2009年12月至2011年12月),并担任KB Home公司的执行副总裁和首席财务官(2009年9月到2009年12月)。他曾担任UST公司高级副总裁和首席财务官(从2007年7月到2009年4月被Altria集团收购)。他曾担任 Swift公司 的执行副总裁兼首席财务官(从2006年到2007年)。他曾担任Cott公司的执行副总裁和首席财务官(从1998年到2005年),负责业务的重组和转型。职业生涯早期,他担任Campbell Soup Company各种职务,责任日益重大(从1979 年到 1997年)。他是Pinnacle Foods公司的董事。他拥有宾夕法尼亚大学的沃顿商学院工商管理硕士学位,是一位特许的成本管理会计师(英国)。


Raymond P. Silcock was named Executive Vice President and Chief Financial Officer in March 2019. Prior to joining Perrigo, Mr. Silcock served as Chief Financial Officer at INW Holdings from 2018 to 2019 and as Executive Vice President and Chief Financial Officer of CTI Foods from 2016 to 2018. In March 2019 CTI Foods filed a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code in U.S. Bankruptcy Court in Delaware. From 2013 until the company's sale in 2016 Mr. Silcock was Executive Vice President and Chief Financial Officer of Diamond Foods, Inc. and previously held Chief Financial Officer roles at UST, Inc., Swift & Co. and Cott Corporation. He also served on the board of Pinnacle Foods, Inc. from 2008 until the company was sold in 2018. His early career was highlighted by an 18-year tenure in positions of increasing responsibility at Campbell Soup Company. Mr. Silcock is a Fellow of the Chartered Institute of Management Accountants UK.
Raymond P. Silcock,他曾担任执行副总裁和首席财务官(2013年6月以来)。加入Diamond之前,他是Great Atlantic & Pacific Tea Company A&P的高级副总裁和首席财务官(2012年3月到2013年2月),也曾担任财政主管(从2011年12月到2011年3月)。他是A&P and Palm Ventures公司的独立管理顾问(从2009年12月至2011年12月),并担任KB Home公司的执行副总裁和首席财务官(2009年9月到2009年12月)。他曾担任UST公司高级副总裁和首席财务官(从2007年7月到2009年4月被Altria集团收购)。他曾担任 Swift公司 的执行副总裁兼首席财务官(从2006年到2007年)。他曾担任Cott公司的执行副总裁和首席财务官(从1998年到2005年),负责业务的重组和转型。职业生涯早期,他担任Campbell Soup Company各种职务,责任日益重大(从1979 年到 1997年)。他是Pinnacle Foods公司的董事。他拥有宾夕法尼亚大学的沃顿商学院工商管理硕士学位,是一位特许的成本管理会计师(英国)。
Raymond P. Silcock was named Executive Vice President and Chief Financial Officer in March 2019. Prior to joining Perrigo, Mr. Silcock served as Chief Financial Officer at INW Holdings from 2018 to 2019 and as Executive Vice President and Chief Financial Officer of CTI Foods from 2016 to 2018. In March 2019 CTI Foods filed a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code in U.S. Bankruptcy Court in Delaware. From 2013 until the company's sale in 2016 Mr. Silcock was Executive Vice President and Chief Financial Officer of Diamond Foods, Inc. and previously held Chief Financial Officer roles at UST, Inc., Swift & Co. and Cott Corporation. He also served on the board of Pinnacle Foods, Inc. from 2008 until the company was sold in 2018. His early career was highlighted by an 18-year tenure in positions of increasing responsibility at Campbell Soup Company. Mr. Silcock is a Fellow of the Chartered Institute of Management Accountants UK.